Cosmo Pharmaceuticals N.V.
https://www.cosmopharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cosmo Pharmaceuticals N.V.
Grünenthal Bolsters US Portfolio With Buyout Of Valinor
Deal snapshot: The German pain-management specialist is acquiring Valinor to gain additional geographic rights to the gastrointestinal drug Movantik and add to its US product portfolio.
Deal Watch: AbbVie Offloads Three Cystic Fibrosis Candidates To Sionna
Plus deals involving Abeona/Beacon, TuHura/Kintara, Crosswalk/Codexis, Lantheus/Life Molecular Imaging as well as tech transfer agreements and small deals involving Pfizer, Sanofi and Ipsen.
Finance Watch: Q2 Ends, Q3 Begins With Latest Group Of VC Mega-Rounds
Private Company Edition: June ended with Formation Bio’s $372m series D round and July began with Beacon’s $170m series B. Also, Curie.Bio raised a $380m fund, Freeflow Ventures emerged with $90m across multiple funds and EvolutionaryScale raised a $142m seed round.
Orphan Drugs Dominate Latest EU Filings
Sotatercept, marstacimab, elafibranor, eplontersen, mirvetuximab soravtansine, troriluzole and tiratricol are among the latest products that the European Medicines Agency has started reviewing for potential EU marketing approval.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Other Names / Subsidiaries
-
- Aries Group, Ltd
- Aries Pharmaceuticals, Inc.
- BioXell
- Cosmo Technologies Limited
- Cosmo Pharmaceuticals S.p.A.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice